Table 4.

Antiplatelet regimen in each study.

Study, year	Antiplatelet	Platelet-resistance testing
Atasoy et al. (10)	DAPT 7–10 days preprocedure, continued clopidogrel once daily for 6–9months and continued aspirin for life (all doses, 75mg daily).	No.
Manning et al. (17)	14/14(100%) patients received SAPT therapy. 2/14(14%) patients were preloaded, and 2/14(14%) patients were loaded immediately postoperatively. The remaining 10/14(71%) patients were loaded intraoperatively.	Not mentioned.
Martinez-Galdamez et al. (12)	Prior to the procedure, 46/50 (92%) patients received DAPT (aspirin +clopidogrel/prasugrel) and 4/50 (8%) patients received SAPT (clopidogrel). 50/50 (100%) patients were prescribed DAPT between ≥1 month and ≤ 1 year post-procedure.	Not mentioned.
Pikis et al. (13)	31/33(94%) patients received DAPT (aspirin 100 mg/day +clopidogrel 75 mg/day) 5 days preprocedure. 1/33(3%) patient received DAPT (aspirin 100 mg/day +prasugrel 10 mg/ day) 5 days preprocedure. 1/33(3%) patient received SAPT (prasugrel 10 mg/ day) 5 days preprocedure. All patients were instructed to continue with the preprocedural antiplatelet regimen until the 6 month angiographic and clinical follow-up.	No.
Rice et al. (14)	195/205 (95.6%) patients received antiplatelet therapy prior to study treatment. DAPT was administered pre- procedure (≥7 days) in 57/195 (29.2%) of subjects, on days 1–6 preprocedure in 104/195 (53.3%), on the day of the procedure in 182/195 (93.3%), and immediately prior to the procedure in 161/195 (82.6%). 193/195 (99%) subjects received DAPT post- procedure, and of these, 20% (39/195) interrupted DAPT within 3 months and continued with SAPT [either aspirin (19.5%) or clopidogrel (0.5%)]. 24/195(12.3%) subjects never interrupted DAPT during follow-up. SAPT was administered pre- procedure (≥7 days) in 4/195 (2.1%) of subjects, on days 1–6 pre- procedure in 9/195 (4.6%), on the day of the procedure in 8/195 (4.1%), and immediately pre- procedure in 13/195 (6.7%). Only 2/195 (1.0%) of subjects received SAPT post- procedure.	Not mentioned.
Trivelato et al. (15)	Patients were asked to take DAPT (aspirin 100 mg/day+ clopidogrel 75 mg/day or ticagrelor 90 mg twice a day) for 5 days prior to the intervention and for 6 months afterward. Aspirin was maintained for another 6 moonths. For ruptured aneurysms, all patients were premedicated with a loading dose of aspirin (300 mg) plus clopidogrel (600 mg) 3 h before the procedure. After treatment, these patients received the standard antiplatelet regimen.	No.
Yeomans et al. (16)	The elective cases received dual antiplatelet therapy post-procedure. The acute cases received single antiplatelet therapy post-procedure. Elective patients received single oral doses of aspirin 300 mg and clopidogrel 600 mg the night before the procedure. The VerifyNow P2Y12 assay (Werfen, Spain) was used to confirm an adequate response to dual antiplatelet therapy. All unruptured, elective aneurysm patients with a good P2Y12 antagonist response were placed on a post-procedure regimen of oral clopidogrel 75 mg once daily for 5 months and oral aspirin 75 mg once daily for 12 months. The procedure would have been abandoned in P2Y12 antagonist non-responders. Poor P2Y12 antagonist responders would have been given oral prasugrel 5–10 mg once daily for 5 months. Acute patients received a single intravenous dose of aspirin 500 mg immediately prior to the deployment of the Pipeline device during the procedure. All acute patients received a single antiplatelet therapy regimen post-procedure of oral aspirin 75 mg once daily for 12 months.	VerifyNow P2Y12 assay.

DAPT, dual antiplatelet therapy; SAPT, single antiplatelet therapy; IV, intravenous injection.